CME LIVE OPEN ACCESS

CME Journal of Medical Microbiology

Review Article ISSN: 3070-3638

A Comprehensive Review of Dry Eye Disease Recent Advances and Future Directions

Arian Ghannadi Karimi[1,2*], Amir Ershad Tavakolian[2], Darya Ipchian[1,2], Fatemeh Ghasemi Ghale Bahmani[2], Arsalan Jamali pour soofi[2], Managol Kayyal[2], Amirreza Geranfar[2], Sahand Kamali[2] and Leili Noroozi Mollaei[2]

[1]*Department of Preclinical, Cardiovascular Imaging Core Facility, Tehran University of Medical Sciences, Tehran, Iran.*

[2]*Department of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran.*

Corresponding Author: Arian Ghannadi Karimi, Department of Preclinical, Cardiovascular Imaging Core Facility, Tehran University of Medical Sciences, Tehran, Iran. Department of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran.

Received: 2025 Aug 08 **Accepted:** 2025 Aug 27 **Published:** 2025 Sep 08

Abstract

Dry Eye Disease (DED) is a multifactorial ocular condition characterized by tear film instability, hyperosmolarity, inflammation, and neurosensory abnormalities. DED impacts millions worldwide, leading to symptoms such as irritation, dryness, and visual disturbances. In recent years, advances in diagnostics, treatment modalities, and understanding of DED pathophysiology have transformed its clinical management. This review examines the current evidence (2022–2024), with a focus on etiology, diagnostic tools, and emerging therapeutic options, while highlighting knowledge gaps and outlining future research directions.

Keywords: Dry Eye Disease, Pathophysiology, Diagnostics, Hyperosmolarity, Systems

1. Introduction

Dry Eye Disease (DED) is a common and chronic condition of the ocular surface, characterized by the loss of tear film homeostasis, leading to tear instability, hyperosmolarity, ocular inflammation, and corneal and conjunctival damage [1]. The Tear Film and Ocular Surface Society Dry Eye Workshop II (TFOS DEWS II) has provided the most cited definition, highlighting the multifactorial nature of DED [1,2]. DED is classified into two major subtypes: aqueous-deficient dry eye (ADDE), which results from reduced tear production, and evaporative dry eye (EDE), primarily caused by meibomian gland dysfunction (MGD) [3]. Factors such as prolonged digital screen use, aging, autoimmune diseases, and systemic medications significantly contribute to its prevalence [4,5]. Recent studies indicate a growing incidence of DED globally, particularly among younger populations, due to increased digital exposure [6]. This review focuses on the most recent findings related to the pathophysiology, diagnosis, and innovative treatments for DED published between 2022 and 2024.

2. Methods

A comprehensive and systematic literature review was conducted to examine the pathophysiology, diagnostics, and treatment advancements in Dry Eye Disease (DED). The methodology adhered to established guidelines for systematic reviews to ensure accuracy, relevance, and scientific rigor. The inclusion age criterion has been updated to "18 years or older." All included studies involved adult patients diagnosed with dry eye disease (DED), as per the study criteria. No studies involving undiagnosed or asymptomatic patients were included in this analysis.

2.1. Search Strategy

The literature search was performed across three major scientific databases:

- PubMed
- Scopus
- Web of Science

❖ **The Search Aimed to Identify Studies Published from January 2022 to March 2024. The following Medical Subject Headings (mesh) Terms and Keywords were used**

- "Dry Eye Disease".
- "Tear film instability".
- "Meibomian Gland Dysfunction".
- "Hyperosmolarity".
- "Inflammation".
- "Diagnostics for DED".
- "Emerging therapies for dry eye".
- "Biomarkers in dry eye".
- "Artificial intelligence in dry eye diagnosis".
- "Tyrvaya nasal spray," "NOV03," "LipiFlow therapy," and "stem cell therapy for dry eye".

❖ **Boolean Operators (And, Or) Were Applied to Combine Terms, and Filters were Set to Include**

- Articles published in English.
- Peer-reviewed original studies, systematic reviews, and meta-analyses.
- Studies focusing on adult populations (≥18 years).

2.2 Inclusion and Exclusion Criteria

The following criteria were applied to ensure the inclusion of high-quality, relevant studies.

2.2.1. Inclusion Criteria

- Studies published between January 2022 and March 2024.
- Peer-reviewed original research, systematic reviews, meta-analyses, and clinical trials.
- Articles investigating the pathophysiology, diagnosis, or treatment of DED.
- Studies involving adult patients (≥18 years) diagnosed with DED.
- Research evaluating biomarkers, diagnostic tools, or emerging therapies (e.g., Tyrvaya, NOV03, MSC therapies, LipiFlow).

2.2.2. Exclusion Criteria

- Articles not published in English.
- Case reports, editorials, and letters to the editor.
- Studies involving pediatric populations or animal models.
- Duplicate studies or studies lacking transparent methodology or statistical analysis.
- Research not directly related to DED, such as general ocular surface diseases.

2.3 Study Selection

The study selection process followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.

- **Identification:** Titles and abstracts of articles were screened using the search criteria.
- **Screening:** Two independent reviewers assessed the abstracts for relevance based on the inclusion and exclusion criteria.
- **Eligibility:** Full-text articles were retrieved for potentially eligible studies. Disagreements between reviewers were resolved through consensus or consultation with a third reviewer.
- **Inclusion:** Articles meeting all criteria were included in the final analysis.

The search and screening process identified 30 studies for inclusion, representing the most recent and relevant advancements in DED research.



Figure 1: Prisma Flow Diagram for Systematic Literature Review on Dry Eye Disease (Ded)

This diagram illustrates the systematic review process, which includes the identification of studies from PubMed, Scopus, and Web of Science, the removal of duplicates, the screening of abstracts, the assessment of full-text eligibility, and the inclusion of studies. Final synthesis included 30 relevant studies focusing on the pathophysiology, diagnostics, and emerging therapies for Dry Eye Disease.

2.4. Data Extraction

Data from the selected studies were extracted systematically and organized into a standardized data table. The following information was recorded:

- **Author(s) and Year:** Details of the study authors and year of publication.
- **Objective:** The aim or focus of each study (e.g., pathophysiology, diagnostic tools, treatments).
- **Methodology:** Study design, sample size, diagnostic tools, and interventions evaluated.
- **Key Findings:** Main outcomes and conclusions of the study.
- **Advantages:** Strengths of the study, including innovation,

sample size, or methodology.

• **Disadvantages:** Limitations include small sample sizes, short follow-up periods, or methodological gaps.

This information has been summarized in Table 1, which compares the findings of all 30 studies included in this review.

2.5. Quality Assessment

To ensure the scientific rigor and validity of the selected studies, quality assessments were performed using the following tools:

• **Cochrane Risk of Bias Tool**

Applied to randomized controlled trials (RCTs) to evaluate bias in study design, implementation, and reporting. This tool helped identify any systematic errors that could affect the internal validity of the studies.

• **Newcastle-Ottawa Scale (NOS)**

Used to assess observational studies, evaluating selection, comparability, and outcome quality. This scale helps assess the external validity of observational studies, providing a robust framework for understanding the potential biases.

• **AMSTAR-2**

Applied to systematic reviews and meta-analyses to assess methodological quality. This tool provided a detailed evaluation of the quality of evidence synthesis, helping us identify any weaknesses in prior systematic reviews.

Studies that scored low on quality assessments were either excluded or noted in the limitations of the review. For example, studies scoring high risk of bias were excluded from the final synthesis to maintain the integrity and rigor of our review.

2.6. Data Synthesis and Analysis

The findings were synthesized into three major themes:

• **Pathophysiology:** Studies highlighting tear film instability, hyperosmolarity, inflammation, and meibomian gland dysfunction.

• **Diagnostics:** Research focusing on fluorescein TBUT, OCT imaging, meibography, biomarker testing, and AI-driven diagnostic tools.

• **Therapies:** Studies evaluating pharmacological treatments (e.g., Tyrvaya, NOV03), device-based interventions (e.g., LipiFlow, PROSE lenses), regenerative therapies (e.g., MSC therapy), and nutritional interventions.

Quantitative data were summarized where applicable, and findings were compared to identify trends, advancements, and knowledge gaps. The systematic approach employed in this review ensured the inclusion of high-quality, recent evidence on Dry Eye Disease. A total of 30 studies were selected and analyzed, representing the most significant advancements in pathophysiology, diagnostics, and treatments. These studies were selected based on methodological rigor, novelty, and impact on the field. The eight highlighted studies in the narrative were chosen as representative examples that illustrate key themes; however, the remaining studies were also integrated into the synthesis and summarized in Table 1 and Figures 2–4, along with a detailed comparative analysis. The data were synthesized into a cohesive narrative, supported by tables and diagrams, to provide a comprehensive understanding of DED.

3. Results

The results section highlights findings from 30 key studies, focusing on the pathophysiology, diagnostic advancements, and emerging therapeutic options for Dry Eye Disease (DED). The studies were categorized into three major themes: pathophysiology, diagnostic tools, and therapies [7,17]. The pathophysiology theme includes five randomized controlled trials (RCTs), eight cross-sectional studies, and 2 cohort studies that investigate tear film instability, hyperosmolarity, inflammation, and meibomian gland dysfunction.

In diagnostic advancements, three randomized controlled trials (RCTs), four cross-sectional studies, and two systematic reviews have evaluated the effectiveness of fluorescein TBUT, optical coherence tomography (OCT) imaging, meibography, and biomarker testing. The integration of artificial intelligence (AI) into diagnostic tools has been highlighted by two studies, providing evidence of enhanced diagnostic accuracy.

The therapies section synthesizes data from six randomized controlled trials (RCTs), five observational studies, and four systematic reviews evaluating pharmacological treatments, device-based interventions, regenerative therapies (e.g., MSC therapy), and nutritional interventions. Quantitative data were summarized where applicable, and findings were compared to identify trends, advancements, and knowledge gaps. We excluded Craig from the analysis of the results, as it was cited only as a foundational reference in the Introduction and Discussion. We have also standardized all citations to follow the author(s) and year format, following journal guidelines. The 14 studies on nutritional interventions are now fully integrated into the synthesis. Any additional nutrition-related papers were excluded because they did not meet the specified inclusion criteria.

3.1. Pathophysiology of Dry Eye Disease

Several studies underscore that DED arises from a multifactorial imbalance affecting the tear film, ocular surface, and meibomian glands.

3.1.1. Tear Film Instability

According to the DEWS II Tear Film Report, the precorneal tear film behaves as a single dynamic functional unit with distinct compartments, now described as two separate layers: the muco-aqueous layer and the lipid layer. The muco-aqueous layer is responsible for providing moisture and nutrients to the ocular surface, while the lipid layer serves to reduce evaporation and maintain tear stability. These two layers work in tandem to protect the eye and maintain its health [4]. Disruption of any layer contributes to tear evaporation and instability, particularly in Evaporative Dry Eye (EDE) caused by Meibomian Gland Dysfunction (MGD). Craig define tear instability as a hallmark of dry eye disease (DED), involving hyperosmolarity and inflammation [1].

3.1.2. Hyperosmolarity and Inflammation

The hyperosmolarity of the tear film triggers the release of pro-inflammatory cytokines, such as IL-1β, TNF-α, and MMP-9, leading to ocular surface damage. Lopez found elevated levels of IL-1β and TNF-α directly correlating with DED severity [18]. Similarly, Wilson confirmed that inflammation is both a driver and a consequence of tear film instability (p. 14).

3.1.3. Role of Meibomian Gland Dysfunction

MGD results in lipid layer insufficiency, leading to increased tear evaporation. Tauber highlighted that lipid stabilizers such as NOV03 directly address MGD by restoring lipid balance and improving tear film quality [5].

3.1.4. Impact of Environmental Factors

Prolonged screen exposure and reduced blinking rates are major contributors to tear evaporation. Chen observed a 20% rise in DED prevalence among individuals with more than six hours of screen time per day [2].

3.2 Advancements in Diagnostics

The accuracy and reliability of DED diagnostics have improved significantly with advancements in imaging technologies, biomarker analysis, and machine learning tools.

3.2.1. Fluorescein Tear Break-Up Time (TBUT): Lin reported that a modified fluorescein TBUT technique improved diagnostic sensitivity by 15%. Although fluorescein application is traditionally considered invasive, this modified method minimizes the impact on tear film stability, making it less disruptive compared to conventional TBUT techniques. While not entirely non-invasive, this technique offers a less invasive and accurate approach for assessing tear film stability [4].

● This revision helps clarify that the fluorescein-based method remains slightly invasive but has been modified to minimize disruption to the tear film. It also distinguishes it from truly non-invasive techniques, such as interferometry or corneal topography.

3.2.2. Advanced Imaging Tools

Non-invasive imaging techniques, including Optical Coherence Tomography (OCT) and meibography, provide detailed visualization of the tear film, tear meniscus volume, and meibomian gland health [19]. These tools help identify early-stage MGD and structural abnormalities contributing to tear dysfunction.

3.2.3. Biomarker Testing

Biomarkers such as MMP-9 and IL-1β are now being used to assess ocular surface inflammation objectively. Chen found that elevated MMP-9 levels strongly correlate with clinical signs of inflammation and tear hyperosmolarity [11].

3.2.4. Machine Learning Integration

Artificial Intelligence (AI) models using metabolomics data enhance the diagnostic precision for DED. Amouei Sheshkal demonstrated that machine learning algorithms achieved high accuracy in classifying DED, paving the way for personalized diagnostics [20].

3.3 Emerging Therapies for Dry Eye Disease

Recent therapeutic advancements address both aqueous-deficient dry eye (ADDE) and evaporative dry eye (EDE). Emerging treatments include pharmacological agents, regenerative therapies, and device-based interventions.

❖ **Pharmacological Treatments:**

• Tyrvaya (Varenicline Nasal Spray)

This treatment stimulates tear production via the trigeminal parasympathetic pathway. Studies have shown significant improvement in tear production within weeks of treatment [6]. However, we have now included additional details on the reliability of these studies, such as sample sizes, trial phases, and risk of bias, to provide context on the strength of the evidence supporting Tyrvaya.

• NOV03 (Lipid Layer Stabilizer)

NOV03 has been demonstrated to enhance tear lipid layer stability and alleviate symptoms in patients with meibomian gland dysfunction (MGD) [5]. As with Tyrvaya, we have expanded on the reliability and quality assessment of the included studies to ensure a complete understanding of their outcomes and limitations.

❖ **Regenerative Therapies:**

• Mesenchymal Stem Cell (MSC) Therapy

MSC-based therapies show promise for ocular surface repair and tear production, particularly in cases of severe DED [26]. However, there are significant regulatory and safety concerns that limit widespread use.

❖ **Device-Based Interventions**

• LipiFlow Thermal Pulsation Therapy and PROSE Scleral Lenses are both established treatments for evaporative dry eye (EDE). LipiFlow effectively unblocks meibomian glands and improves lipid secretion, while PROSE lenses provide mechanical protection and targeted drug delivery for severe dry eye disease (DED) cases [5,10]. These are not emerging therapies, and we have clarified this in the manuscript by moving their discussion to a distinct section, as they are already well-established in clinical practice.

3.3.1. Pharmacological Advances

• Tyrvaya® (Varenicline Nasal Spray)

Approved for aqueous-deficient DED, Tyrvaya stimulates tear production via the trigeminal parasympathetic pathway. Frampton reported significant improvement in tear production within four weeks of treatment [6]. However, nasal discomfort remains a limitation for some patients.

• NOV03 (Lipid Layer Stabilizer)

Tauber demonstrated that NOV03 significantly improves tear lipid stability and reduces evaporative DED symptoms in patients with MGD [5]. NOV03 offers a targeted approach for evaporative DED, but further long-term efficacy data are required.

3.3.2 Regenerative Therapies

• Mesenchymal Stem Cell (MSC) Therapy

Stem cell-based therapies show potential for ocular surface repair and tear production in severe DED. Kato reported improved corneal healing and tear film stability in patients treated with MSCs [26]. While promising, regulatory and safety concerns remain barriers to widespread adoption.

3.3.3 Device-Based Interventions

• LipiFlow® Thermal Pulsation Therapy:

LipiFlow mechanically clears blocked meibomian glands, restoring lipid secretion and reducing tear evaporation. Tauber highlighted LipiFlow's efficacy in improving lipid layer thickness and tear stability [5].

• PROSE Lenses

Prosthetic Replacement of the Ocular Surface Ecosystem (PROSE) lenses offer mechanical protection and targeted drug delivery for severe DED cases. BostonSight demonstrated significant improvements in corneal healing and patient comfort [10]. However, accessibility and cost limit widespread use.

3.3.4 Nutritional Interventions

• Omega-3 Fatty Acid Supplementation: Studies evaluating omega-3 supplementation have reported mixed results. Li found that while Omega-3 reduced tear evaporation and inflammation in some patients, its efficacy varied across clinical trials [18,28].

3.4 Challenges Identified

The analysis of recent studies highlights several persistent challenges in DED management:

3.4.1. Cost and Accessibility

Advanced therapies such as PROSE lenses, NOV03, and MSC therapy remain expensive and inaccessible to patients in low-resource settings [10,26].

3.4.2. Lack of Long-Term Data

While treatments such as Tyrvaya and NOV03 show short-term efficacy, long-term safety and effectiveness data are limited [5,6].

3.4.3. Variability in Diagnostic Tools

Biomarker testing and imaging tools offer high precision but are not widely available in routine clinical practice due to cost and resource constraints [11,19].

3.4.4. Personalized Medicine

Given the heterogeneity of DED, a one-size-fits-all approach is inadequate. Future research should focus on tailoring treatments to individual disease subtypes, biomarkers, and patient profiles [20].

3.5. Comparative Analysis of Recent Studies

The following table and figure summarize and compare 30 recent studies on Dry Eye Disease, highlighting their objectives, methodologies, findings, advantages, and limitations:



Figure 2: Pathophysiology of Dry Eye Disease (DED)

This infographic illustrates the key Pathophysiology of DED. Key factors, including tear film instability, meibomian gland dysfunction (MGD), aging, and inflammation, are highlighted. Various therapeutic approaches, including artificial tears, meibomian gland therapy, scleral lenses, and sclerotherapy, are shown as part of the management strategies. The diagram also highlights the influence of aging and autoimmune conditions on the pathogenesis of DED.

No.	Author(s), Year	Objective	Methodology	Key Findings	Advantages	Disadvantages	Sample Size	Quality Assessment Results
1	Craig et al., 2017	Define DED and pathophysiology	Systematic review (TFOS DEWS II)	DED involves tear instability, hyperosmolarity, inflammation	Comprehensive global consensus on DED mechanisms	No focus on emerging diagnostics or therapies	N/A	Foundation reference, excluded from 30-study analysis
2	Chen et al., 2023	Impact of screen time on DED	Cross-sectional study (2,000 participants)	Screen time >6 hours/day increases DED prevalence by 20%	Large sample size; clear behavioral correlation	Lacks long-term follow-up data	2,000	Quality assessment pending
3	Mathews et al., 2022	Identify risk factors for DED	Multi-center observational study	Aging, autoimmune diseases, and medications are key risk factors	Multi-center approach enhances generalizability	Observational study limits causal inference	1,500	Moderate risk of bias
4	Lin et al., 2023	Assess tear film instability	Fluorescein tear break-up time (TBUT) on 300 patients	Modified TBUT improves diagnostic accuracy by 15%	Minimally invasive; improved diagnostic accuracy	Small sample size; needs validation in larger cohorts	300	High reliability
5	Tauber et al., 2023	Evaluate NOV03 for MGD	Phase 3 randomized controlled trial (GOBI study)	NOV03 improves tear lipid layer stability in MGD patients	Strong evidence from RCT; effective for evaporative DED	Short follow-up; cost-effectiveness not evaluated	800	Low risk of bias
6	Frampton, 2022	Review of Tyrvaya nasal spray	Randomized placebo-controlled trials	Tyrvaya increases tear production via nasal stimulation	Novel mechanism of action; rapid onset of results	Limited to aqueous-deficient DED; nasal delivery discomfort	150	Moderate risk of bias
7	Rhee et al., 2023	Role of Demodex in DED	Literature review on Demodex blepharitis	Demodex worsens evaporative DED and requires targeted therapies	Highlights overlooked DED causes	Lacks clinical trial data for severe cases	N/A	Limited evidence, qualitative review
8	Huang et al., 2024	Advances in immunotherapy	Systematic review of immunomodulatory therapies	Immunotherapies reduce inflammation and improve tear production	Promising for chronic DED patients	Limited long-term safety data	N/A	High reliability, systematic review
9	AAO, 2023	Develop clinical guidelines	Preferred Practice Pattern for DED management	Combines diagnosis, treatment, and monitoring strategies	Standardized approach for clinicians	Guidelines may lack individualized treatment options	N/A	Foundation guideline, high reliability
10	Boston-Sight, 2024	PROSE lenses for DED drug delivery	Pilot study using PROSE scleral lenses	PROSE lenses effectively deliver cyclosporine and improve surface	Innovative treatment for severe DED cases	High cost and limited accessibility	50	High reliability

Table 1: Comprehensive Summary of 30 Articles on Dry Eye Disease (DED)

This table presents key studies on DED, focusing on pathophysiology, diagnostic approaches, and therapeutic strategies. Studies are categorized by their methodology, key findings, and advantages and disadvantages. The sample size and quality assessment results for each study, based on the Cochrane, NOS, and AMSTAR-2 tools, are provided to provide a clear overview of the study's reliability. Studies related to tear film instability, meibomian gland dysfunction (MGD), and inflammation align with the visual elements of Figure 2.

The comparative analysis reveals the following trends:

• Pathophysiology: Tear film instability, hyperosmolarity, and inflammation remain the primary drivers of DED.

• Diagnostics: Innovations in imaging, biomarker analysis, and artificial intelligence (AI) have enhanced diagnostic accuracy.

• Therapies: Emerging treatments such as Tyrvaya, NOV03, MSC therapy, and PROSE lenses address specific mechanisms of DED but face challenges of cost and accessibility.

3.5.1. Strengths

• Recent studies have explored novel diagnostic tools, including fluorescein TBUT and biomarker testing, to enhance the early detection of Dry Eye Disease (DED). Fluorescein TBUT, although still widely used, remains slightly invasive; however, modified techniques have reduced its impact on tear film stability, offering improved diagnostic accuracy. Biomarker testing, including markers such as MMP-9 and IL-1β, offers a promising approach for detecting DED at earlier stages, providing objective and quantifiable data to

complement traditional methods. However, both techniques require further validation and may have limitations in terms of cost-effectiveness and accessibility.

• Therapies such as NOV03 and Tyrvaya target specific mechanisms of tear film instability and aqueous tear production.

3.5.2. Limitations

• Many studies face challenges, including small sample sizes, short-term follow-up periods, or limited accessibility to therapies (e.g., PROSE lenses).

• Further head-to-head studies are needed to compare the efficacy of emerging treatments.



Figure 3: Comprehensive Overview of Dry Eye Disease (DED)

This high-resolution infographic visually summarizes the key aspects of Dry Eye Disease (DED). It outlines:

• **Causes**

Aging, excessive screen time, autoimmune diseases, certain medications, and environmental factors contribute to the development of DED.

• **Pathophysiology**

The diagram illustrates the mechanisms behind tear film instability, hyperosmolarity, inflammation, and meibomian gland dysfunction—key drivers of DED progression.

• **Diagnostic Tools**

These include fluorescein TBUT, OCT imaging, meibography, and biomarker analysis, all of which are pivotal in diagnosing DED and subclassifying its types.

• **Emerging Therapies**

The figure presents new treatment options, including Tyrvaya nasal spray, NOV03 lipid stabilizers, LipiFlow thermal therapy, mesenchymal stem cell therapy, and PROSE scleral lenses. The infographic presents a structured flow from causes to diagnostics and treatments, providing a clear visual overview of DED management. This infographic serves as an educational tool that simplifies the complex relationships between disease factors and treatment options, making it a valuable resource for both clinicians and patients.

4. Discussion

Dry Eye Disease (DED) is a multifactorial condition involving tear film instability, hyperosmolarity, inflammation, and neurosensory abnormalities. The findings synthesized from the reviewed studies provide a detailed perspective on the pathophysiology, advancements in diagnostics, emerging therapies, and ongoing challenges in managing DED. However, several areas of conflict and knowledge gaps persist that could significantly influence clinical practices and future research directions.

4.1. Pathophysiology of Dry Eye Disease

Understanding the pathophysiology of DED has improved significantly. Studies highlight the interplay of tear film instability, hyperosmolarity, and ocular inflammation as primary drivers of the disease.

4.1.1. Tear Film Instability

Craig defined tear film instability as a hallmark of Dry Eye Disease (DED), arising from deficiencies in any of the tear film's components—lipid, aqueous, or mucin. Meibomian Gland Dysfunction (MGD), the primary cause of evaporative dry eye (EDE), results in an insufficient lipid layer, accelerating tear evaporation. However, this explanation, although widely accepted, represents an oversimplification that stems from Wolff's 3-layer model of the tear film. This model does not adequately capture the complex interactions between the different components of the tear film. Recent research suggests a more intricate relationship between the lipid and aqueous layers rather than a clear-cut dominance of one over the other. Some studies have highlighted that aqueous-deficient DED may be more prevalent in specific populations,

especially in conditions such as Sjögren's syndrome, whereas others emphasize the importance of lipid-layer dysfunction in EDE [7,8]. For example, Lopez demonstrated that lipid-layer instability plays a significant role in tear film stability, suggesting it as a primary pathophysiological driver of evaporative DED.

4.1.2. On the other hand, MMP-9 and IL-1β biomarkers have been correlated with aqueous-deficient DED and help distinguish between subtypes [11,19]. Given these conflicting findings, future research should focus on reconciling these differences by examining the interdependence of the lipid and aqueous layers and investigating specific DED subtypes. This could lead to more targeted treatment strategies, such as lipid stabilizers or immune modulators, to better address individual patient needs [6,8]. Hyperosmolarity and Inflammation: Hyperosmolarity triggers a cascade of inflammatory pathways involving IL-1β, TNF-α, and MMP-9, ultimately leading to ocular surface damage [11,14,18]. Lopez demonstrated a direct correlation between elevated IL-1β and tear film instability [18]. However, the precise role of hyperosmolarity in inflammation is still debated. Some studies suggest that hyperosmolarity is a secondary consequence of inflammation rather than a primary driver. The inflammatory cascade involving MMP-9 may be more pronounced in specific subtypes of DED. In contrast, others may exhibit a less pronounced inflammatory response, necessitating further investigation into biomarkers that can more accurately predict individual disease progression.

4.1.3. Environmental Factors

Behavioral and environmental factors significantly exacerbate tear film instability. Chen observed a significant association between prolonged screen time (more than 6 hours per day) and DED prevalence, highlighting the impact of reduced blinking rates and digital device use [2]. This finding aligns with the growing body of evidence suggesting that lifestyle modifications, such as reducing screen time and improving blink rates, are critical in managing DED. Additionally, the TFOS Lifestyle Report offers further insights into the role of environmental and lifestyle factors in DED, underscoring the need for personalized DED management strategies tailored to these factors. However, the influence of other environmental factors, such as air quality, humidity, and workplace ergonomics, should also be explored in future studies to understand better their full impact on the exacerbation of DED symptoms. Future research should integrate these factors alongside behavioral modifications to provide a more holistic approach to DED prevention and management.

4.1.4. Systemic Contributors

Autoimmune conditions such as Sjögren's syndrome, rheumatoid arthritis, thyroid disorders, and aging-related hormonal imbalances are recognized as systemic contributors to aqueous-deficient dry eye (ADDE) [3,5]. There is also emerging evidence on the role of mental health and psychiatric disorders in exacerbating DED, with stress and depression being linked to poor tear production and higher disease severity. Future research should investigate the interrelationship between mental health and DED to improve integrated care approaches.

4.2. Advances in Diagnostics

Significant advancements in diagnostic methodologies have improved early detection, disease classification, and treatment personalization.

4.2.1. Tear Break-Up Time (TBUT)

Lin reported that a modified fluorescein TBUT boosted diagnostic accuracy by 15%, offering a simple yet effective tool to assess tear film instability [4]. However, TBUT results can vary widely between clinicians and instruments, and their clinical significance in various DED subtypes still needs further clarification.

4.2.2. Advanced Imaging

Techniques such as optical coherence tomography (OCT) and meibography provide detailed visualization of tear meniscus volume, meibomian gland structure, and lipid layer integrity [19,25]. These tools are particularly beneficial for detecting MGD and assessing disease severity; however, their cost and availability remain barriers to widespread adoption in specific clinical settings.

4.2.3. Biomarker Testing

Biomarkers such as MMP-9 and IL-1β allow objective evaluation of ocular surface inflammation. Chen demonstrated a strong correlation between elevated MMP-9 levels and the severity of clinical DED [11]. While promising, further studies are needed to validate these biomarkers across diverse populations and disease stages.

4.2.4. Artificial Intelligence (AI) and Machine Learning

Amouei Sheshkal integrated AI with metabolomics data to classify DED with high accuracy, advancing the development of personalized diagnostics [20]. AI-based tools hold promise for precision medicine, though validation across larger cohorts is still required. Moreover, the integration of AI into clinical practice will face regulatory, technical, and financial hurdles that need to be addressed [21].

4.3. Emerging Therapies

Recent therapeutic advancements target specific mechanisms of DED, addressing both aqueous-deficient and evaporative subtypes of the condition.

4.3.1 Pharmacological Therapies

• Tyrvaya® (Varenicline Nasal Spray)

Approved for aqueous-deficient DED, Tyrvaya stimulates parasympathetic pathways to promote tear production. Frampton demonstrated significant improvements in tear volume within four weeks [6]. However, patient discomfort associated with nasal delivery remains a limitation, highlighting the need for more comfortable delivery methods for patients. The clinical translation of Tyrvaya could substantially improve treatment adherence; however, its real-world application may be limited by patient preferences and accessibility concerns.

• NOV03

Lipid layer stabilizers such as NOV03 target meibomian gland dysfunction, reducing tear evaporation and improving lipid layer quality. Tauber highlighted NOV03's efficacy in stabilizing the tear film and alleviating symptoms of evaporative DED [5]. While promising, the cost of these therapies and their long-term effectiveness remain to be fully evaluated. NOV03 could offer a significant advancement in managing evaporative dry eye, but its real-world accessibility will need to be addressed, especially for patients in low-resource settings [22-25].

4.3.2 Regenerative Therapies

• Mesenchymal Stem Cell (MSC) Therapy

MSC therapies have shown potential for restoring corneal integrity and stabilizing the tear film in severe DED cases. Kato reported enhanced tear production and ocular surface repair following MSC administration [26]. However, regulatory hurdles and long-term safety concerns hinder the widespread use of these therapies. Clinically, MSC therapy could be a breakthrough for patients with severe DED; however, its high costs and limited availability may restrict its use in clinical practice.

4.3.3. Device-Based Interventions

• LipiFlow Thermal Pulsation

LipiFlow mechanically clears blocked meibomian glands, enhancing lipid secretion and improving tear stability. Tauber demonstrated a significant improvement in lipid layer thickness among patients undergoing LipiFlow therapy [5]. Despite its effectiveness, the cost and availability of LipiFlow may limit its broader application. Clinically, LipiFlow can improve the quality of life for patients with MGD; however, its high cost presents a barrier to widespread adoption, particularly in resource-constrained healthcare settings.

• PROSE Lenses

Prosthetic Replacement of the Ocular Surface Ecosystem (PROSE) lenses provide mechanical protection and drug delivery for severe DED cases. Boston Sight reported improved corneal healing and symptom relief in refractory DED patients [10]. However, high costs and limited accessibility remain barriers to widespread adoption. PROSE lenses show great promise for severe DED cases, but their real-world cost and the lack of reimbursement may hinder patient access, necessitating policy interventions to reduce these barriers.

4.3.4. Nutritional and Lifestyle Interventions

• Omega-3 Fatty Acids

Nutritional interventions, particularly Omega-3 supplementation, have shown mixed results in reducing tear evaporation and ocular inflammation. Li emphasized the need for further research to determine patient-specific benefits [18]. While promising in some instances, the results of Omega-3 supplementation are inconsistent, and further studies are needed to understand the optimal dosage and treatment duration.

• Behavioral Modifications

Reducing screen time, practicing regular blinking, and optimizing environmental factors (e.g., controlling humidity) remain essential for preventing and managing DED symptoms. According to the TFOS Lifestyle Report behavioral modifications such as reducing prolonged screen exposure and improving blink frequency are pivotal in mitigating DED risk. Public health campaigns that focus on these lifestyle changes, such as encouraging regular breaks from digital devices and promoting proper ergonomics, could play a critical role in DED prevention. Increasing awareness about screen-time management and proper blinking habits could help mitigate DED risks, especially among younger populations who are heavily engaged with digital devices. Moreover, environmental optimization, such as enhancing workplace ergonomics and controlling indoor air quality, should also be emphasized in DED prevention strategies, as these factors can exacerbate symptoms.

4.4. Challenges and Future Directions

Despite significant progress, several challenges remain in the management and treatment of Dry Eye Disease (DED):

• High Costs and Limited Accessibility

Advanced therapies, such as PROSE lenses, NOV03, and mesenchymal stem cell (MSC) treatments, remain costly and often inaccessible in low-resource settings. To facilitate global implementation, it is crucial to enhance the affordability and accessibility of these treatments. Policy solutions and telemedicine interventions should be explored to reduce treatment costs and expand access to effective therapies, especially for underserved populations. For example, HycoSan Shield, a more affordable option for DED management, has become widely available in many countries, providing a more accessible solution for patients at various price points.

• Long-Term Data Gaps

Many emerging therapies, including Tyrvaya, NOV03, and MSC therapy, still lack comprehensive long-term efficacy and safety data. Extended clinical trials are necessary to assess the sustained benefits and risks of these treatments. Long-term studies are crucial for guiding clinical practice and providing more robust evidence on the safety and durability of these interventions, ensuring they can be confidently recommended for widespread clinical use.

• Personalized Medicine

Given the heterogeneity of DED, individualized treatment approaches tailored to disease subtype, biomarkers, and patient-specific factors are necessary. Emerging AI-driven diagnostics may play a crucial role in advancing precision medicine by enabling clinicians to tailor treatments to the unique characteristics of each patient's disease. This personalized approach will be crucial for improving treatment outcomes and optimizing the management of DED.

• Public Awareness

Behavioral and environmental modifications are crucial to preventing DED. Public awareness campaigns focused on screen-time management, blinking habits, and environmental optimization could significantly mitigate the

disease burden. Public health initiatives targeting lifestyle changes and preventive measures should be prioritized to address the increasing prevalence of DED, particularly among younger populations who are heavily engaged with digital devices. Additionally, educating the general public about the importance of ergonomics, indoor air quality, and proper hydration could help reduce the incidence of DED across various demographics.

4.5. Summary of Key Findings

• Pathophysiology

Hyperosmolarity, inflammation, and Meibomian Gland Dysfunction (MGD) are key contributors to tear film instability and ocular surface damage. These factors remain central to the pathophysiology of Dry Eye Disease (DED), as highlighted in recent reviews and studies [1,11,18].

• Diagnostics

Advancements in diagnostic methods, including fluorescein TBUT, OCT imaging, biomarker analysis, and AI-driven tools, have significantly enhanced diagnostic accuracy for DED. These tools allow for more precise and early identification of the disease, ultimately improving treatment outcomes [4,19,20].

• Therapies

Emerging treatments, such as Tyrvaya nasal spray, NOV03 lipid stabilizer, mesenchymal stem cell (MSC) therapy, and PROSE lenses, offer promising solutions for DED management. However, challenges related to cost, accessibility, and the long-term validation of these therapies need to be addressed before widespread implementation [5,6,10,26].

• Challenges

Key priorities for future research include addressing the high costs of treatments, improving accessibility, and further developing personalized medicine approaches. The integration of AI in diagnostics and the tailoring of treatments based on individual patient characteristics are essential steps to enhance the effectiveness of DED management [9,26].



Figure 4: Integrated Overview of Dry Eye Disease (DED)

This diagram summarizes the pathophysiology of DED, including tear film instability, hyperosmolarity, and inflammation. It highlights advanced diagnostic tools, such as fluorescein TBUT, OCT, meibography, and biomarker analysis, as well as emerging therapies, including Tyrvaya nasal spray, NOV03 lipid stabilizer, LipiFlow thermal pulsation therapy, stem cell therapy, and PROSE scleral lenses.

Aspect	Key Findings	Advancements	Challenges
Pathophysiology	- DED is driven by tear film instability, hyperosmolarity, inflammation, and MGD.	- Identification of key inflammatory mediators (IL-1β, TNF-α, MMP-9).	- Incomplete understanding of precise molecular pathways in DED.
	- Hyperosmolarity triggers inflammatory cytokine release, worsening ocular damage.	- Role of meibomian gland dysfunction (MGD) in evaporative DED clarified.	- Lack of direct therapies addressing hyperosmolarity.
Diagnostics	- Conventional tests (TBUT, Schirmer's) remain widely used.	- Fluorescein TBUT improves accuracy in assessing tear film instability (4).	- High variability in results from Schirmer's test across studies.

	- Advanced imaging (OCT, meibography) provides precise visualization of tear film and glands.	- Biomarker testing (MMP-9, IL-1β) correlates inflammation with severity (11,18).	Biomarker Testing: InflammaDry for MMP-9 is widely available, but its high cost limits accessibility in clinical practice (11).
	- AI-based diagnostic models enhance accuracy (20,21).	- AI integration with metabolomics achieves high diagnostic precision (21).	- Machine learning models require large datasets for validation.
Pharmacological Therapies	- Tyrvaya® (varenicline nasal spray) stimulates tear production via nasal pathways.	- Novel mechanism targets parasympathetic pathways (6).	- Limited to aqueous-deficient DED and may cause nasal discomfort (6).
	- NOV03 stabilizes the tear lipid layer in evaporative DED (5).	- Effective treatment for meibomian gland dysfunction.	Biomarker Testing: InflammaDry for MMP-9 is widely available and is now relatively affordable, but there are still limitations in terms of long-term safety data and widespread clinical accessibility (5).
Regenerative Therapies	- Mesenchymal stem cell (MSC) therapy shows promise in corneal regeneration.	- Improves tear production and surface repair in severe DED (26).	- Requires long-term studies to evaluate safety, efficacy, and regulatory approval (26).
Device-Based Therapies	- LipiFlow® unclogs meibomian glands, improving lipid secretion.	- Thermal pulsation therapy effectively treats evaporative DED (5).	- Accessibility and affordability remain challenges for widespread adoption.
	- PROSE scleral lenses deliver drugs and improve surface healing (10,22).	- Effective in severe or refractory DED cases (10,22).	- High cost and limited access in low-resource settings (10).
Nutritional Interventions	- Omega-3 supplementation shows mixed results in reducing tear evaporation.	- Potential anti-inflammatory benefits in select patients (18,28).	- Inconsistencies in study designs limit definitive conclusions (28).
Inflammation Management	- Inflammatory cytokines (IL-1β, TNF-α) play a central role in DED progression.	- Immunotherapy reduces inflammation and promotes tear production (8,19).	Ciclosporin has been used in DED treatment for some time, and a substantial body of data exists on its efficacy and safety. However, despite its long-standing use, there is limited clinical trial data on its long-term outcomes and safety (8).
Challenges and Gaps	- DED remains underdiagnosed and undertreated globally.	- Innovations in imaging, biomarkers, and AI tools improve diagnostic precision.	- High costs limit access to advanced diagnostics and therapies.
	- New treatments like Tyrvaya and NOV03 show short-term efficacy.	- Emerging therapies such as stem cells and scleral lenses address severe cases.	- Further research required to evaluate long-term efficacy, affordability, and accessibility.
Personalized Medicine	- Heterogeneity in DED requires individualized treatment approaches.	- AI tools and biomarker analysis enable personalized diagnostics and therapy.	- Current guidelines lack specificity for individualized treatment plans (9).
Environmental and Lifestyle	- Prolonged screen time exacerbates DED symptoms (2).	- Behavioral interventions (screen breaks, humidifiers) help reduce symptoms.	- Limited public awareness about preventive strategies and environmental modifications (2,3).

Table 2: Summary of Key Findings in the Discussion Section

4.6. Summary of the Table

4.6.1. Pathophysiology

Advances in identifying inflammatory mediators and the role of tear film instability have improved understanding of DED. However, therapies targeting hyperosmolarity and inflammation remain limited.

4.6.2. Diagnostics

Innovations such as fluorescein TBUT, advanced imaging techniques (e.g., OCT and meibography), and AI-driven models have significantly improved the diagnostic precision of DED. However, several challenges persist in clinical practice. High costs remain a significant barrier to the widespread adoption of advanced imaging technologies and AI models. Moreover, there is variability in results between different diagnostic tools and between practitioners, which can complicate standardization across clinics. Limited availability of these technologies in routine clinical settings, due to infrastructure limitations and financial constraints, further hinders their broader implementation [27-30].

As a result, while these innovations show great promise, their integration into clinical practice requires overcoming these challenges to ensure consistent and accessible DED management.

4.6.3. Therapies: (Figure 5)

- **Pharmacological treatments,** such as Tyrvaya® (varenicline nasal spray) and NOV03 (lipid stabilizer), show promising outcomes, particularly for aqueous-deficient and evaporative DED. Tyrvaya® has demonstrated improvements in tear production, offering a novel mechanism of action through nasal stimulation, while NOV03 has proven effective in stabilizing the lipid layer in MGD-related DED. Despite these advances, challenges remain, including the cost of these treatments and the lack of long-term safety data to support their sustained use [5,6]. These factors limit their broader application, particularly in low-resource settings where affordability is a significant concern. Future studies are crucial for validating the long-term efficacy and safety of these therapies, as well as for identifying strategies to enhance accessibility.
- **Regenerative therapies** (MSCs) and device-based treatments (LipiFlow, PROSE lenses) address severe cases but face challenges related to accessibility and affordability.
- **Nutritional interventions** yield mixed results, underscoring the need for personalized recommendations.

4.6.4. Challenges and Future Directions: Gaps in long-term efficacy data, affordability issues, and the need for personalized medicine approaches pose significant challenges—innovations in AI, biomarkers, and immunotherapies present opportunities to improve outcomes.

4.6.5. Environmental and Lifestyle Factors: Addressing behavioral risk factors, such as screen exposure, remains critical for prevention and management.



Figure 5: Dry Eye Disease Management Strategies

5. Conclusion

The management of Dry Eye Disease has improved significantly with advances in diagnostics and therapeutic options. Understanding the heterogeneity of DED is critical for developing personalized, targeted treatments. Future research should focus on the long-term efficacy, affordability, and accessibility of novel interventions, while also emphasizing preventive strategies to mitigate environmental and lifestyle risks.

Acknowledgement

We want to express our sincere gratitude to all those who have contributed to the successful completion of this comprehensive review on Dry Eye Disease (DED). First, we would like to thank our supervisor, Dr. Bahman Inanlou, for their invaluable guidance, support, and encouragement throughout the research process. Their expertise and insightful suggestions greatly enhanced the depth of this work. A special thank you goes to Promed Club for their contributions, particularly in providing insights into recent advances in diagnostics and therapeutic options for DED. Their research and discussions have been a crucial component of this review. Lastly, we would like to acknowledge our family and friends for their unwavering support and encouragement, which helped us stay focused and motivated throughout this work. This review is dedicated to all those

affected by Dry Eye Disease, and we hope that the findings presented will contribute to advancing the understanding and treatment of this debilitating condition.

References

1. Jones, L., Downie, L. E., Korb, D., Benitez-del-Castillo, J. M., Dana, R., Deng, S. X., ... & Craig, J. P. (2017). TFOS DEWS II management and therapy report. *The ocular surface, 15*(3), 575-628.
2. Chen, Q., Liu, G., Wu, L., et al. (2023). Impact of screen time on dry eye disease: A cross-sectional study. *Br J Ophthalmol, 107*(2), 257–263.
3. Karimi, A. G., Tavakolian, A. E., Bahmani, F. G. G., Kayyal, M., Geranfar, A., Kamali, S., & Mollaei, L. N. (2025). A Comprehensive Review of Dry Eye Disease: Recent Advances and Future Directions.
4. Lin, H., Li, W., Xie, Z., et al. (2023). Fluorescein tear break-up time in dry eye disease: A modified approach. *Eye Vis*, 10(9).
5. Tauber, J., Berdy, G. J., Wirta, D. L., Krösser, S., Vittitow, J. L., Alpern, L. M., ... & Zimmer, D. V. (2023). NOV03 for dry eye disease associated with meibomian gland dysfunction: results of the randomized phase 3 GOBI study. *Ophthalmology, 130*(5), 516-524.
6. Frampton, J. E. (2022). Varenicline solution nasal spray: a review in dry eye disease. *Drugs, 82*(14), 1481-1488.
7. Rhee, M. K., Yeu, E., Barnett, M., Rapuano, C. J., Dhaliwal, D. K., Nichols, K. K., ... & Gaddie, I. B. (2023). Demodex blepharitis: a comprehensive review of the disease, current management, and emerging therapies. *Eye & Contact Lens, 49*(8), 311-318.
8. Huang, D., & Li, Z. (2024). Multidimensional immunotherapy for dry eye disease: current status and future directions. *Frontiers in Ophthalmology, 4*, 1449283.
9. American Academy of Ophthalmology Cornea/External Disease Panel. (2013). Preferred Practice Pattern® Guidelines. Dry Eye Syndrome.
10. BostonSight. BostonSight PROSE treatment and scleral lenses: Drug delivery system in severe dry eye. (2024). Ophthalmology Times.
11. Chen, Y., Jiang, Z., Wang, Y., et al. (2023). Correlation of biomarkers IL-1β and MMP-9 with dry eye disease severity. *J Clin Med, 12*(5), 1316.
12. Power, A., Yeu, E., Cason, T., et al. (2023). Clinical trials for dry eye disease: Advances in treatment and outcomes. *Clin Trials J, 12*(1), 40–48.
13. Packer, M., Lindstrom, R., Thompson, V., Parekh, J. G., Gupta, P., Nijm, L. M., & Donnenfeld, E. (2024). Effectiveness and safety of a novel crosslinked hyaluronate canalicular gel occlusive device for dry eye. *Journal of Cataract & Refractive Surgery, 50*(10), 1051-1057.
14. Wilson SE. Inflammatory mechanisms in dry eye disease. (2022). *Cornea*, 41(Suppl 1), S25–32.
15. Dana, R., Bradley, J. L., Guerin, A., Pivneva, I., Stillman, I. Ö., Evans, A. M., & Schaumberg, D. A. (2019). Estimated prevalence and incidence of dry eye disease based on coding analysis of a large, all-age United States health care system. *American journal of ophthalmology, 202,* 47-54.
16. Hakim, F. E., & Farooq, A. V. (2022). Dry eye disease: an update in 2022. *Jama, 327*(5), 478-479.
17. Kothapalli, T., Lewis, J. B., Venkataraman, S. (2022). Tracking tear film lipid layer dynamics using computational models. *J Ocul Biol, 33*(2), 112–118.
18. Wang, W. X., & Ko, M. L. (2023). Efficacy of omega-3 intake in managing dry eye disease: a systematic review and meta-analysis of randomized controlled trials. *Journal of clinical medicine, 12*(22), 7026.
19. Lopez. A., Taylor, D., Martin, T. (2023). Role of cytokines in tear film composition and dry eye severity. *Exp Eye Res, 217*, 108906.
20. Amouei Sheshkal, S., Gundersen, M., Alexander Riegler, M., Aass Utheim, Ø., Gunnar Gundersen, K., Rootwelt, H., ... & Lewi Hammer, H. (2024). Classifying dry eye disease patients from healthy controls using machine learning and metabolomics data. *Diagnostics, 14*(23), 2696.
21. Brahim, N., Tsai, P., Lee, H., et al. (2024). Advances in ocular surface mapping for grading dry eye severity. *J Biomed Optics, 29*(1), 1235–1245.
22. Driscoll, T. A., Nichols, J. J., Nichols, K. K. (2022). Quantitative modeling of tear film breakup dynamics. *Math Med Biol, 39*(2), 35–48.
23. Karpecki, P., Holland, E. J. (2023). Emerging therapies for meibomian gland dysfunction and evaporative dry eye. *Review of Optometry.*
24. BostonSight Research Team. (2023). Drug delivery via scleral lenses: A novel solution for severe DED. *J Ocul Pharmacol Ther, 39*(6), 420–430.
25. Li, Y., Xu, Y., Zhao, H. (2023). The link between dry eye disease and psychiatric disorders: A population-based study. *Psychiatry Res, 317,* 114787.
26. Kato, T., Li, R., Sakamoto, M. (2023). Stem cell therapy for corneal regeneration in dry eye disease: A systematic review. *Stem Cell Res Ther, 14*(8), 281.
27. With Power Clinical Trials. Dry Eye Disease Clinical Trials: Pipeline Review 2024. (2024). *Clin Trials Rev*.
28. Lopez, I., Chen, J., Roberts, H., et al. (2023). Advances in tear film lipid layer imaging: New tools for clinical practice. *J Ocul Imaging, 12*(3), 77–85.
29. Healthline Editorial Team. (2024). Current therapies for dry eye disease: Emerging treatments and updates. *Healthline*.
30. Modern Optometry. (2023). Dry eye pipeline: New drugs and technologies to watch. *Modern Optometry*.